649 results on '"Uemura, Hiroji"'
Search Results
2. Laparoscopic removal of retroperitoneal schwannoma in renal hilum: a case report
3. Association of PSA variability with prostate cancer development using large-scale medical information data: a retrospective cohort study
4. Localized amyloidosis of the ureter: a case report
5. Transurethral laser lithotripsy using the Mitrofanoff urethral conduit for bladder stones: a case report
6. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
7. A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL
8. Enzalutamide Prolonged the Duration of Drug Use in Comparison to Abiraterone Acetate and Cabazitaxel after Upfront Docetaxel: A Large Japanese Database Study.
9. A diagnostically challenging case of inflammatory myofibroblastic tumor primary to the peritoneum
10. Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study
11. Correlation between Higher Aging Males’ Symptoms Scores and a Higher Risk of Lower Urinary Tract Symptoms
12. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
13. Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan
14. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
15. Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases
16. Shared decision making, physicians’ explanations, and treatment satisfaction: a cross-sectional survey of prostate cancer patients
17. Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
18. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
19. The impact of smoking on male lower urinary tract symptoms (LUTS)
20. The efficacy of microsurgical varicocelectomy as a salvage option for grade 1 varicocele: a retrospective study
21. A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
22. Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer
23. Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial.
24. Sperm cryopreservation for fertility preservation in male patients with cancer at a single-center in Japan
25. Additional file 2 of Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
26. Additional file 1 of Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
27. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer
28. Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab
29. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study
30. Reactive oxygen species measured in the unprocessed semen samples of 715 infertile patients
31. Gastrointestinal cancer and bilateral hydronephrosis resulted in a high risk of ureteral stent failure
32. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
33. Skene duct adenocarcinoma in a patient with an elevated serum prostate-specific antigen level: a case report
34. Microsurgical varicocelectomy for intratesticular varicocele with a history of orchiopexy for undescended testis
35. Corrigendum to 'What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021' [Eur Urol 2022]
36. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study.
37. Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis
38. aPKCλ/ι Promotes Growth of Prostate Cancer Cells in an Autocrine Manner through Transcriptional Activation of Interleukin-6
39. A qualitative research study in Japan investigating patients’ experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment
40. The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer
41. Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
42. Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment
43. 不妊を契機に発見された多精巣症の1例
44. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer
45. A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
46. A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy
47. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer
48. A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer
49. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level
50. Additional file 1 of Shared decision making, physicians’ explanations, and treatment satisfaction: a cross-sectional survey of prostate cancer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.